Seeking AlphaSat, 09 May 2026 00:31:16 GMTBioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease TranscriptBIOA+5.22%
MarketBeatFri, 08 May 2026 20:02:37 GMTBioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC TrialsBIOA+5.22%
Seeking AlphaFri, 24 Apr 2026 22:41:31 GMTBioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor TranscriptBIOA+5.22%
BenzingaTue, 21 Apr 2026 15:07:05 GMTBioAge Labs Stock Gains After Positive Early Data And Pipeline PlansBIOA+5.22%
Zacks Investment ResearchTue, 21 Apr 2026 14:57:07 GMTWall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should KnowBIOA+5.22%
Seeking AlphaWed, 15 Apr 2026 20:20:55 GMTBioAge Labs: Oral NLRP3 Inhibitor Could Establish PoC In CV This YearBIOA+5.22%
